Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Inclusion Criteria

• •A diagnosis of asthma (according to GINA 2016) for a period of at least 6 months.
• •Treated with medium dose inhaled corticosteroid (ICS), or high dose ICS, or low dose ICS plus long- acting beta agonist (LABA), or low dose ICS plus leukotriene receptor antagonist (LTRA), or medium dose ICS plus LABA for at least 3 months prior to Visit 1 and the doses have been stable for at least 4 weeks prior to Visit 1.
• •FEV1 of ≤85% for patients aged ≥18 years. FEV1 of ≤90% for patients aged 12 to \<18 years.
• •Daytime asthma symptom score (0 to 6 scale) of ≥1 per day during 4 of the last 7 days of the placebo run- in period.
• •Total daily SABA use ≥1 puff per day during 4 of the last 7 days of the placebo run-in period.
• •Demonstrated reversible airway obstruction.
• •Asthma control questionnaire (ACQ) score ≥ 1.5.